STAAR Surgical (STAA) guided second quarter 2026 net sales to more than $90 million, compared with $44.3 million a year earlier. This update immediately puts revenue momentum at the center of the investment debate.

The latest guidance lands against a mixed trading backdrop for STAAR Surgical, with the share price down 20.18% over the past month and 12.43% over the past quarter. The 1 year total shareholder return is 21.45%, but the 5 year total shareholder return is down 81.77%, signaling pressure over the longer term even as revenue expectations reset higher.

If STAAR Surgical's updated outlook has your attention, this could be a useful moment to widen your watchlist and check out 40 healthcare AI stocks

STAAR Surgical shares have dropped sharply even as the stock trades below both analyst targets and some intrinsic value estimates. Where does a reasonable fair value range actually sit before you mark this up or down on your watchlist?

Most Popular Narrative: 21.2% Undervalued

STAAR Surgical's most followed narrative pegs fair value at $29.67, above the last close of $23.38, putting its recent sell off in a different light.

STAAR Surgical has significant cash reserves and no debt, providing a strong financial base to manage current challenges, adjust production, and invest selectively in growth. If conditions improve, this flexibility could support more stable earnings and offer upside to the current narrative.

Curious what kind of revenue ramp and margin rebuild might support that fair value, and how long it could take to get there? The narrative leans heavily on a multi year earnings transition with richer profitability assumptions than the recent past, plus a premium future earnings multiple. The key question is which mix of growth, margins, and valuation the market might actually accept.

Result: Fair Value of $29.67 (UNDERVALUED)

However, STAAR Surgical's reliance on a single distributor in China, prior inventory build up, and weaker refractive procedure assumptions could easily challenge this optimistic setup.

Another View on STAAR Surgical's Valuation

The first narrative leans on discounted cash flows and a fair value of $29.67 for STAAR Surgical. Yet on a simple P/S basis, the stock trades at about 4x, compared with 2.8x for the wider US Medical Equipment industry and 1.5x for peers, while the fair ratio is 3.4x. That gap can signal valuation risk if sentiment cools or an opportunity if the market eventually moves closer to that fair ratio. Which outcome do you think is more realistic?

For a closer look at how this price compares with cash flows and earnings expectations, including where valuation pressure or support might come from, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If the mixed signals around STAAR Surgical have you on the fence, this is the moment to review the underlying data yourself and move quickly to shape your own view, starting with the 2 key rewards

Looking for more investment ideas beyond STAAR Surgical?

If STAAR Surgical is on your radar, do not stop there. Broaden your opportunity set with a few focused stock ideas tailored to different investing angles.

• Target potential bargains by scanning companies priced below their estimated value with the 50 high quality undervalued stocks
• Prioritise resilience by focusing on companies highlighted in the 84 resilient stocks with low risk scores
• Spot lesser known opportunities that still boast solid fundamentals using the screener containing 20 high quality undiscovered gems

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.